Dive Brief: Karuna Therapeutics has submitted an application seeking Food and Drug Administration approval of KarXT, a drug that works in a new way to treat schizophrenia. While current treatments act ...

Patients with migraine spontaneously described typical symptoms like pain but only revealed cognitive symptoms after being asked further questions, according to a speaker at the American Headache ...

Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can ...

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Incyte named former Karuna Therapeutics and Anthos Therapeutics exec Bill Meury as CEO. Vistagen appoints Elissa Cote as chief corporate development officer. Inizio Evoke, a 2025 MM+M Agency 100 ...

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Find out why INCY stock is a Buy.

About UTILITY therapeutics Ltd. UTILITY has exclusive U.S. commercial rights to two European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections (UTI).

LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class ...

LONDON, UK / ACCESS Newswire / July 3, 2025 / UTILITY therapeutics Ltd. (UTILITY), a biotechnology company focused on the development of PIVYA (pivmecillinam 185 mg tablets), a penicillin class ...